← Back to Search

Genetic Testing

Fetal Genome Profiling for Fetal Growth Restriction

N/A
Waitlist Available
Led By Kangpu Xu, PhD, DVM
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks post pregnancy
Awards & highlights

Study Summary

This trial will test whether cells from the early pregnancy can be used for prenatal testing, which could improve early pregnancy management.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks post pregnancy
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks post pregnancy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of chromosomal anomalies as detected via fetal genome analysis of trophoblast cells
Secondary outcome measures
Occurrence of chromosomal anomalies detected via trophoblast cell analysis as compared to occurrence of chromosomal anomalies detected via preimplantation genetic testing (PGT), chorionic villi sampling (CVS), amniocentesis, or cytogenetic results.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Fetal Genome ProfilingExperimental Treatment1 Intervention
Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,061 Previous Clinical Trials
1,316,377 Total Patients Enrolled
Kangpu Xu, PhD, DVMPrincipal InvestigatorWeill Medical College of Cornell University
~0 spots leftby Jun 2025